Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.26997 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Emily Mitchell und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Benzodioxoles, Cystic Fibrosis Transmembrane Conductance Regulator, Indoles, Cystic Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
The authors declare no conflict of interest. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Emily Mitchell, Dana Albon
Förderung
- None
Zitieren
APA
Mitchell, E., & Albon, D. (2024). Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants. Pediatric Pulmonology. https://doi.org/10.1002/ppul.26997
Vancouver
Mitchell E, Albon D. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants. Pediatric Pulmonology. 2024. doi:10.1002/ppul.26997
BibTeX
@article{Mitchell2024,
author = {Mitchell, Emily and Albon, Dana},
title = {Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.26997}
}
EUVIMED